Bradford, William H.
Zhang, Jing
Gutierrez-Lara, Erika J.
Liang, Yan
Do, Aryanne
Wang, Tsui-Min
Nguyen, Lena
Mataraarachchi, Nirosh
Wang, Jie
Gu, Yusu
McCulloch, Andrew
Peterson, Kirk L.
Sheikh, Farah http://orcid.org/0000-0003-2610-0125
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL142251, HL162369, HL121754)
LEXEO Therapeutics Inc.
Additional Ventures, Joe and Clara Tsai Foundation
Article History
Received: 23 March 2023
Accepted: 16 October 2023
First Online: 7 December 2023
Competing interests
: F.S. was a co-founder of Stelios Therapeutics (acquired by LEXEO Therapeutics) and is a co-founder and shareholder of Papillon Therapeutics Inc as well as a consultant and shareholder of LEXEO Therapeutics Inc. A.M. is a co-founder of and equity holder in Insilicomed Inc and Vektor Medical Inc. For A.M., findings reported in this study did not involve the companies he is involved with in any way, and these findings have no relationship with the business activities or scientific interests of either company. All other authors declare no competing interests.